Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 101 - 150 of 1864 results
- DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells.
- Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate.
- A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death.
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
- IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
- Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth.
- Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.
- Antibody-based antiangiogenic cancer therapy.
- A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells.
- A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
- Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
- Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia.
- Membrane HSP70: the molecule triggering gammadelta T cells in the early stage of tumorigenesis.
- Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer.
- Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
- IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
- A novel human monoclonal antibody derived from tumor-infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes.
- Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.
- Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
- Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
- Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment.
- Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.
- Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection.
- Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
- Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
- Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells.
- In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation.
- Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
- Generation of antigen-presenting cells using cultured dendritic cells and amplified autologous tumor mRNA.
- Immunohistochemical detection of CD 95 (Fas) & Fas ligand (Fas-L) in plasma cells of multiple myeloma and its correlation with survival.
- Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides.
- Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
- Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.
- Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
- Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
- FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.
- Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
- Supernatural T cells: genetic modification of T cells for cancer therapy.
- Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
- Characterization of the gammadelta T cell response to acute leukemia.
- CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.
- Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
- CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
- Identification of the pentapeptide constituting a dominant epitope common to all eukaryotic heat shock protein 90 molecular chaperones.
- Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
- A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis.
- A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model.
- VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.